Cryoport inc
Officers & Directors
Jerrell W. Shelton. Mr. Shelton became a member of our board of directors in October
2012 and was appointed President and Chief Executive Officer of the Company in
November 2012. He was appointed Chairman of the Board in October 2015. He served
on the Board of Directors and standing committees of Solera Holdings, Inc. from
April 2007 through November 2011. From June 2004 to May 2006, Mr. Shelton was
the Chairman and CEO of Wellness, Inc., a provider of advanced, integrated hospital
and clinical environments. Prior to that, he served as Visiting Executive to IBM
Research and Head of IBM’s WebFountain. From October 1998 to October 1999,
Mr. Shelton was Chairman, President and CEO of NDC Holdings II, Inc. Between October
1996 and July 1998, he was President and CEO of Continental Graphics Holdings,
Inc. And from October 1991 to July 1996, Mr. Shelton served as President and CEO
of Thomson Business Information Group. Mr. Shelton has a B.S. in Business Administration
from the University of Tennessee and an M.B.A. from Harvard University. Mr. Shelton
currently serves on the Advisory Board of Directors of the Smithsonian Institution
Library. Mr. Shelton’s extensive leadership, management, strategic planning
and financial expertise through his various leadership and directorship roles
in public, private and global companies, makes him well-qualified to serve as
a member of the board of directors.
Richard J. Berman. Mr. Berman became a member of our board of directors in January
2015, and serves as Chairman of the Audit and Compensation Committee and member
of the Nominating and Governance Committee of the Board. Mr. Berman’s business
career spans over 35 years of venture capital, senior management and merger &
acquisitions experience. In the past 5 years, Mr. Berman has served as a director
and/or officer of over a dozen public and private companies. From 2006 to 2011,
he was Chairman of National Investment Managers, a company with $12 billion in
pension administration assets. Mr. Berman is a director of four public healthcare
companies: Advaxis, Inc., Caldarius, Inc. (formerly Neostem, Inc.), MetaStat Inc.
and Cryoport Inc. From 2002 to 2010, he was a director of Nexmed Inc. where he
also served as Chairman/CEO in 2008 and 2009 (formerly Apricus Biosciences, Inc.);
From 1998 to 2000, he was employed by Internet Commerce Corporation (now Easylink
Services) as Chairman and CEO, and was a director from 1998 to 2012. Previously,
Mr. Berman worked at Goldman Sachs; was Senior Vice President of Bankers Trust
Company, where he started the M&A and Leveraged Buyout Departments; created
the largest battery company in the world in the 1980’s by merging Prestolite,
General Battery and Exide to form Exide Technologies (XIDE); helped to create
what is now Soho (NYC) by developing five buildings; and advised on over $4 billion
of M&A transactions. He is a past Director of the Stern School of Business
of NYU where he obtained his BS and MBA. He also has U.S. and foreign law degrees
from Boston College and The Hague Academy of International Law, respectively.
Mr. Berman’s financial and business expertise, including his background
in biotechnology, international management and banking, and his extensive experience
as a director in the public company context makes him well-qualified to serve
as a member of the board of directors.
Robert Hariri, M.D., Ph.D. Dr. Hariri, M.D., PhD. became a member of our board
of directors in September 2015. Dr. Hariri has been the chairman, founder and
chief scientific officer of Celgene Cellular Therapeutics, a division of Celgene
Corporation, since 2005. Prior to joining Celgene Cellular Therapeutics as president
in 2002, Dr. Hariri was founder, chairman and chief scientific officer at Anthrogenesis
Corporation/LIFEBANK, Inc., a privately held biomedical technology and service
corporation involved in the area of human stem cell therapeutics, which was acquired
by Celgene in 2002. Dr. Hariri is also co-founder and president of Human Longevity,
Inc., a genomics and cell-therapy company. He serves on numerous Boards of Directors
including Myos Corporation (Nasdaq: MYOS), Provista Diagnostics and Bionik Laboratories
Corp (OTCQX: BNKL) and is a member of the Board of Visitors of the Columbia University
School of Engineering &Applied Sciences and the Science &Technology Council
of the College of Physicians and Surgeons; as well as a member of the Scientific
Advisory Board for the Archon X PRIZE for Genomics, which is awarded by the X
Prize Foundation. Dr. Hariri is also a Trustee of the J. Craig Venter Institute
and the Liberty Science Center and has been appointed Commissioner of Cancer Research
by New Jersey Governor, Chris Christie. Dr. Hariri was recipient of the Thomas
Alva Edison Award in 2007 and 2011, and has received numerous other honors for
his many contributions to biomedicine and aviation. Dr. Hariri received his undergraduate
training at Columbia College and Columbia University School of Engineering and
Applied Sciences and was awarded his M.D. and Ph.D. degrees from Cornell University
Medical College. Dr. Hariri received his surgical training at The New York Hospital-Cornell
Medical Center where he also directed the Aitken Neurosurgery Laboratory and the
Center for Trauma Research. Dr. Hariri’s training as a scientist, his knowledge
and experience with respect to the biomedical and pharmaceutical industries and
his extensive research and experience makes him well-qualified to serve as a member
of the board of directors.
Ramkumar Mandalam, Ph.D. Dr. Mandalam became a member of our board of directors
in June 2014. He is member of the Compensation Committee and Governance and Nominating
Committee. Dr. Mandalam is the President and CEO of Cellerant Therapeutics, Inc.,
a clinical stage biotechnology company developing novel cell-based and antibody
therapies for cancer treatment and blood-related disorders. Prior to joining Cellerant
in 2005, he was the Executive Director of Product Development at Geron Corporation,
a biopharmaceutical company where he managed the development and manufacturing
of cell based therapies for treatment of degenerative diseases and cancer. From
1994 to 2000, he held various positions in research and development at Aastrom
Biosciences, where he was responsible for programs involving ex vivo expansion
of human bone marrow stem cells and dendritic cells. Dr. Mandalam received his
Ph.D. in Chemical Engineering from the University of Michigan, Ann Arbor, Michigan.
Dr. Mandalam is the author or co-author of several publications, patent applications,
and abstracts. Dr. Mandalam’s training as a scientist, extensive background
in biotechnology and management expertise and makes him well-qualified to serve
as a member of the board of directors.
Edward J. Zecchini. Mr. Zecchini became a member of our board of directors in
September 2013, and serves as Chairman of the Nominating and Governance Committee
of the Board and member of the Audit Committee and the Compensation Committee.
Mr. Zecchini currently serves as Chief Information Officer at Remedy Partners,
Inc. Prior to that, Mr. Zecchini served as Executive Vice President and Chief
Technology Officer at Sandata Technologies, LLC, from May 2010 to March 2014,
President and Chief Executive Officer of IT Analytics LLC from March 2008 to April
2010, Executive Vice President of Operations and Chief Information Officer of
Touchstone Healthcare Partnership from May 2007 to February 2008 and Senior Vice
President and Chief Information Officer of HealthMarkets, Inc. from October 2004
to April 2007. Earlier in his career he held senior level positions at Thomson
Healthcare and SportsTicker, Inc. Mr. Zecchini has over thirty years of experience
in the healthcare and information technology industries. Mr. Zecchini holds a
Bachelor of Arts degree from the State University of New York at Oswego. Mr. Zecchini’s
business expertise, including his background and extensive experience information
technology and management makes him well-qualified to serve as a member of the
board of directors.
Robert S. Stefanovich. Mr. Stefanovich became Chief Financial Officer, Treasurer
and Corporate Secretary for the Company in June 2011 following the Company’s
filing of its Form 10–K for the fiscal year ended March 31, 2011. From June
15, 2012 to November 4, 2012, Mr. Stefanovich served as the Principal Executive
Officer of the Company. From November 2007 through March 2011, Mr. Stefanovich
served as Chief Financial Officer of Novalar Pharmaceuticals, Inc., a venture-backed
specialty pharmaceutical company. Prior to that, he held several senior positions,
including interim Chief Financial Officer of Xcorporeal, Inc., a publicly traded
medical device company, Executive Vice President and Chief Financial Officer of
Artemis International Solutions Corporation, a publicly traded software company,
Chief Financial Officer and Secretary of Aethlon Medical Inc., a publicly traded
medical device company and Vice President of Administration at SAIC, a Fortune
500 company. Mr. Stefanovich also served as a member of the Software Advisory
Group and an Audit Manager with Price Waterhouse LLP’s (now PricewaterhouseCoopers)
hi-tech practice in San Jose, CA and Frankfurt, Germany. He currently also serves
as a board member of Project InVision International, a provider of business performance
improvement solutions. He received his Masters of Business Administration and
Engineering from University of Darmstadt, Germany.
Cryoport inc currently has 31 employees.
|
|